ARE WORMS THE KEY TO THE HUMAN GENOME?

December 8, 2000

SCIENCE & ENGINEERING NEWS

San Francisco, CALIF. — Naomi Aoki reports for the Boston Globe that it was December 1998 when scientists said they had sequenced the genome of a tiny earthworm called the nematode as a test run for mapping the human genome.

Peter Hansen and Petra Krauledat remember it well. The husband-and-wife team had just built a machine for a small Cambridge company to study the creatures. And they had lost a lot of money on the contract.

Then, suddenly, this obscure little worm was propelled to international scientific celebrity. Its genetic makeup, it turned out, was remarkably similar to that of humans. It could help scientists understand the role of certain genes and develop drugs to treat diseases such as Alzheimer’s and diabetes.

“In 1998, nobody had even heard of this worm other than some nerdy biologists,” said Petra Krauledat, a biologist herself and president of Union Biometrica Inc. “By mid-1999, every drug company had a program using these nematodes.”

And the machine that Hansen and Krauledat had considered a financial loss had suddenly become the key to unlocking the nematode’s potential – and their company’s.

The machine could do in a few weeks what took scientists peering through microscopes more than a year to do. It could test tens of thousands of drug candidates on hundreds of thousands of living nematodes, identifying those that work. And, eventually, Hansen and Krauledat said, it could drastically shrink the time, risks and cost of drug discovery for humans.

“One of the lessons of the human genome project is that automation is essential to basic life-science research,” said Hansen, a physicist and Union Biometrica’s chairman and chief technology officer. “The day of the white- coated laboratory researcher is gone.”

Drug discovery is an expensive and risky business. Out of 10,000 promising compounds, only one will make it to market. It will take an average of 15 years and $300 million to get there. And more than half of that money will be spent before the drug even reaches human clinical trials.

The very survival of pharmaceutical and biotechnology companies depends on improving those odds. As medicine advances, drug companies are tackling more complex and elusive diseases. They are pouring more money into research, meaning they must also deliver more drugs to stay financially healthy.

At the same time, the public outcry over drug pricing is increasing, forcing companies to explore more cost-effective and less risky ways of developing drugs. The crush of data streaming out of genomic research is also demanding faster and more systematic approaches to drug discovery.

Faced with these challenges, drug and biotech companies are turning to robotics, optics and high-performance computing to speed the pace of drug discovery.

Robots stack, move and place trays of cells onto machines that record the cells’ reactions to various doses of drugs. Computers systematically match libraries of drug compounds with models of genes. Huge databases of genetic information scan other databases for similar genes.

But the automation typically stops when drug compounds leave the research bench to be tested on mice or other animals. Scientists genetically alter the mice to mimic human diseases, give them the test drug, observe them and later autopsy the mice to determine if the drug had any effect.

The process is time-consuming, labor-intensive and costly. It can take months for researchers to study a reaction in the mice. Often, the discoveries are made only after killing and dissecting the mice to study their biological responses to the disease and the drug.

That’s why pharmaceutical companies and the scientific community greeted with open arms the surprise discovery that nematodes and humans were genetically similar.

Compared to mice, nematodes are cheap and easy to study. The worms are transparent, allowing researchers to track a gene inserted into a nematode under a microscope by adding a fluorescent protein to the gene. And if a drug turns off the gene – a sign that the drug is working – the glow disappears.

The worms also reproduce quickly, making hundreds of exact copies of themselves in a few days. And since they are tiny (one-millimeter long as adults), they can be easily stored in small petri dishes or test tubes.

But there are some drawbacks. Their size and tendency to wiggle make them tricky to catch. Scientists peer through microscopes, grabbing the worms with a sliver of platinum wire. The work is tedious and tiresome. And although faster than testing on mice, it takes days to analyze 1,000 nematodes.

By automating the process, however, Hansen and Krauledat have shrunk days’ worth of work into a single minute. And in doing so, they invented the only automated system of testing living organisms. The machine also can be adjusted to test other small, simple organisms such as fruit flies and zebra fish.

Called the COPAS Technology Platform, the automated testing system feeds the creatures one by one into a tube and through a scanning system that reads the fluorescent genes. The more the worm or fruit fly glows, the more active the disease.

The scanner relays the information to the computer, which plots the worm on an on-screen image according to its age and level of disease. The computer then instructs the machine to sort the worm accordingly.

The COPAS system does all this at the rate of 100 nematodes per second. In a rapid-fire fashion, researchers can test thousands of drug compounds and spot the ones that dim the glowing genes. They can also weed out compounds that seem to have toxic side effects.

Historically, when researchers have begun testing a drug on a mouse, they’ve known very little about the drug. It looks promising when tested against tissue samples or single cells in a test tube or petri dish. But they have no information about how it might work in a living organism.

Testing on nematodes or other simple organisms can help narrow down the candidates that move through the pipeline, reducing the risks and costs of failing later in the process.

The testing machine costs between $200,000 and $700,000, depending on the complexity of the system. So far, companies that have bought it are using it as an intermediate testing stop between the lab and the mouse.

As the technology spreads, however, Hansen and Krauledat said it could be used to replace lab tests on cells and tissue samples, making testing on nematodes and other simple creatures the first and last step before testing on mice.

On average, Krauledat said, it now costs a company $200 million to get a drug from the idea stage to the first human clinical trial. Hansen and Krauledat said their technology can shrink that number to $50 million over the next five years.

Hansen and Krauledat said they haven’t advertised the machine or published their findings in scientific journals. Indeed, references to Union Biometrica are few and far between in the mainstream media. They’ve been too busy, they say, to worry about publicity.

Word of mouth, however, has brought some of the world’s largest pharmaceutical companies to their door. Among their customers are industry giants like AstraZeneca PLC, Aventis SA, Johnson & Johnson, Novartis AG, SmithKline Beecham, and Glaxo Wellcome PLC.

In May, after a decade of supporting the private company on revenue from their contract work, Hansen and Krauledat accepted $2 million in venture capital. It was time, they decided, to concentrate on developing and marketing their new technology without the distraction of scrambling for cash.

The Somerville, Mass., company will finish this year with $4 million in sales, a figure Hansen and Krauledat expect to double next year. With a backlog of 130 labs interested in the machine, they said, their biggest problem is hiring people to meet the demand.

“To find out what all these newly discovered genes do and how to make drugs that affect them is going to require new kinds of equipment and new ways of doing things,” Hansen said. “That’s what we’re really offering – new ways to study disease and discover drugs to treat those diseases.”

============================================================

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industry updates delivered to you every week!

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion XL — were added to the benchmark suite as MLPerf continues Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing power it brings to artificial intelligence.  Nvidia's DGX Read more…

Call for Participation in Workshop on Potential NSF CISE Quantum Initiative

March 26, 2024

Editor’s Note: Next month there will be a workshop to discuss what a quantum initiative led by NSF’s Computer, Information Science and Engineering (CISE) directorate could entail. The details are posted below in a Ca Read more…

Waseda U. Researchers Reports New Quantum Algorithm for Speeding Optimization

March 25, 2024

Optimization problems cover a wide range of applications and are often cited as good candidates for quantum computing. However, the execution time for constrained combinatorial optimization applications on quantum device Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at the network layer threatens to make bigger and brawnier pro Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HBM3E memory as well as the the ability to train 1 trillion pa Read more…

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing po Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HB Read more…

Nvidia Looks to Accelerate GenAI Adoption with NIM

March 19, 2024

Today at the GPU Technology Conference, Nvidia launched a new offering aimed at helping customers quickly deploy their generative AI applications in a secure, s Read more…

The Generative AI Future Is Now, Nvidia’s Huang Says

March 19, 2024

We are in the early days of a transformative shift in how business gets done thanks to the advent of generative AI, according to Nvidia CEO and cofounder Jensen Read more…

Nvidia’s New Blackwell GPU Can Train AI Models with Trillions of Parameters

March 18, 2024

Nvidia's latest and fastest GPU, codenamed Blackwell, is here and will underpin the company's AI plans this year. The chip offers performance improvements from Read more…

Nvidia Showcases Quantum Cloud, Expanding Quantum Portfolio at GTC24

March 18, 2024

Nvidia’s barrage of quantum news at GTC24 this week includes new products, signature collaborations, and a new Nvidia Quantum Cloud for quantum developers. Wh Read more…

Alibaba Shuts Down its Quantum Computing Effort

November 30, 2023

In case you missed it, China’s e-commerce giant Alibaba has shut down its quantum computing research effort. It’s not entirely clear what drove the change. Read more…

Nvidia H100: Are 550,000 GPUs Enough for This Year?

August 17, 2023

The GPU Squeeze continues to place a premium on Nvidia H100 GPUs. In a recent Financial Times article, Nvidia reports that it expects to ship 550,000 of its lat Read more…

Shutterstock 1285747942

AMD’s Horsepower-packed MI300X GPU Beats Nvidia’s Upcoming H200

December 7, 2023

AMD and Nvidia are locked in an AI performance battle – much like the gaming GPU performance clash the companies have waged for decades. AMD has claimed it Read more…

DoD Takes a Long View of Quantum Computing

December 19, 2023

Given the large sums tied to expensive weapon systems – think $100-million-plus per F-35 fighter – it’s easy to forget the U.S. Department of Defense is a Read more…

Synopsys Eats Ansys: Does HPC Get Indigestion?

February 8, 2024

Recently, it was announced that Synopsys is buying HPC tool developer Ansys. Started in Pittsburgh, Pa., in 1970 as Swanson Analysis Systems, Inc. (SASI) by John Swanson (and eventually renamed), Ansys serves the CAE (Computer Aided Engineering)/multiphysics engineering simulation market. Read more…

Choosing the Right GPU for LLM Inference and Training

December 11, 2023

Accelerating the training and inference processes of deep learning models is crucial for unleashing their true potential and NVIDIA GPUs have emerged as a game- Read more…

Intel’s Server and PC Chip Development Will Blur After 2025

January 15, 2024

Intel's dealing with much more than chip rivals breathing down its neck; it is simultaneously integrating a bevy of new technologies such as chiplets, artificia Read more…

Baidu Exits Quantum, Closely Following Alibaba’s Earlier Move

January 5, 2024

Reuters reported this week that Baidu, China’s giant e-commerce and services provider, is exiting the quantum computing development arena. Reuters reported � Read more…

Leading Solution Providers

Contributors

Comparing NVIDIA A100 and NVIDIA L40S: Which GPU is Ideal for AI and Graphics-Intensive Workloads?

October 30, 2023

With long lead times for the NVIDIA H100 and A100 GPUs, many organizations are looking at the new NVIDIA L40S GPU, which it’s a new GPU optimized for AI and g Read more…

Shutterstock 1179408610

Google Addresses the Mysteries of Its Hypercomputer 

December 28, 2023

When Google launched its Hypercomputer earlier this month (December 2023), the first reaction was, "Say what?" It turns out that the Hypercomputer is Google's t Read more…

AMD MI3000A

How AMD May Get Across the CUDA Moat

October 5, 2023

When discussing GenAI, the term "GPU" almost always enters the conversation and the topic often moves toward performance and access. Interestingly, the word "GPU" is assumed to mean "Nvidia" products. (As an aside, the popular Nvidia hardware used in GenAI are not technically... Read more…

Shutterstock 1606064203

Meta’s Zuckerberg Puts Its AI Future in the Hands of 600,000 GPUs

January 25, 2024

In under two minutes, Meta's CEO, Mark Zuckerberg, laid out the company's AI plans, which included a plan to build an artificial intelligence system with the eq Read more…

Google Introduces ‘Hypercomputer’ to Its AI Infrastructure

December 11, 2023

Google ran out of monikers to describe its new AI system released on December 7. Supercomputer perhaps wasn't an apt description, so it settled on Hypercomputer Read more…

China Is All In on a RISC-V Future

January 8, 2024

The state of RISC-V in China was discussed in a recent report released by the Jamestown Foundation, a Washington, D.C.-based think tank. The report, entitled "E Read more…

Intel Won’t Have a Xeon Max Chip with New Emerald Rapids CPU

December 14, 2023

As expected, Intel officially announced its 5th generation Xeon server chips codenamed Emerald Rapids at an event in New York City, where the focus was really o Read more…

IBM Quantum Summit: Two New QPUs, Upgraded Qiskit, 10-year Roadmap and More

December 4, 2023

IBM kicks off its annual Quantum Summit today and will announce a broad range of advances including its much-anticipated 1121-qubit Condor QPU, a smaller 133-qu Read more…

  • arrow
  • Click Here for More Headlines
  • arrow
HPCwire